Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
Arthritis Care & Research · 2024
DOI: 10.1002/acr.25339 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Arthritis Care & Research, 2024. Verfasst von Melissa L Mannion und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Antirheumatic Agents, Etanercept, Registries. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Food and Drug Administration, NIAMS NIH HHS, Purdue Pharma.
Abstract (Originalsprache)
Objective
The objective of this study was to compare the effectiveness of a second tumor necrosis factor inhibitor (TNFi) versus a non‐TNFi biologic following discontinuation of a TNFi for patients with polyarticular‐course juvenile idiopathic arthritis (pJIA).
Methods
Using the Childhood Arthritis and Rheumatology Research Alliance Registry, patients with pJIA who started receiving a second biologic following a first TNFi were identified. Patients were required to have no active uveitis on the index date and a visit six months after the index date. Outcome measures included Clinical Juvenile Arthritis Disease Activity Score with a maximum of 10 active joints (cJADAS10), cJADAS10 inactive disease (ID; ≤2.5) and cJADAS10 minimal disease activity (MiDA; ≤5). Multiple imputation was used to account for missing data. Adjusted odds ratios (aORs) were calculated using propensity score quintiles to compare outcomes at six months following second biologic initiation.
Results
There were 216 patients included, 84% initially received etanercept, and most patients stopped receiving it because of its ineffectiveness (74%). A total of 183 (85%) started receiving a second TNFi, and 33 (15%) started receiving a non‐TNFi. Adalimumab was the most common second biologic received (71% overall, 84% of second TNFi), and tocilizumab was the most common non‐TNFi second biologic received (9% overall, 58% of non‐TNFi). There was no difference between receiving TNFi versus non‐TNFi in cJADAS10 ID (29% vs 25%; aOR 1.23, 95% confidence interval [CI] 0.47–3.20) or at least MiDA (43% vs 39%; aOR 1.11, 95% CI 0.47–2.62) at six months.
Conclusion
Most patients with pJIA started receiving TNFi rather than non‐TNFi as their second biologic, and there were no differences in disease activity at six months. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham.
- Childhood Arthritis and Rheumatology Research Alliance, Washington, DC.
- Duke University and Duke Clinical Research Institute, Durham, North Carolina.
- Boston Children's Hospital, Massachusetts.
- University of Minnesota, Minneapolis.
- The University of Manchester, Manchester, United Kingdom.
ORCID-Profile: Melissa L Mannion, Stephen Balevic, Colleen K Correll, Lianne Kearsley-Fleet
Förderung
- U.S. Food and Drug Administration
- NIAMS NIH HHS
- Purdue Pharma
- Manchester Biomedical Research Centre
- Childhood Arthritis and Rheumatology Research Alliance
- NIH HHS
- Patient-Centered Outcomes Research Institute
- Rheumatology Research Foundation
Zitieren
APA
Mannion, M. L., Amin, S., Balevic, S., Chang, M. L., Correll, C. K., Kearsley-Fleet, L., Hyrich, K. L., Beukelman, T., & Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators (2024). Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care & Research. https://doi.org/10.1002/acr.25339
Vancouver
Mannion ML, Amin S, Balevic S, Chang ML, Correll CK, Kearsley-Fleet L, et al. Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care & Research. 2024. doi:10.1002/acr.25339
BibTeX
@article{Mannion2024,
author = {Mannion, Melissa L and Amin, Shahla and Balevic, Stephen and Chang, Min-Lee and Correll, Colleen K and Kearsley-Fleet, Lianne and Hyrich, Kimme L and Beukelman, Timothy and Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators, Childhood Arthritis and Rheumatology Research Alliance Registry Investigators and the UK Juvenile Idiopathic Arthritis Biologics Register Investigators},
title = {Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis},
journal = {Arthritis Care & Research},
year = {2024},
doi = {10.1002/acr.25339}
}
EUVIMED